METTL3 and cancer: During pancreatic cancer progression, NKAP leads to the overmaturation of miR-25 under overexpressed METTL3 m6A modification, thereby inhibiting PHLPP2 and activating the AKT-p70S6K signaling to promote cancer progression (80).